Abstract
TNBC, also known as triple-negative breast cancer, is a predominantly female-targeting and stands out due to its defining attribute. TNBC accounts for a considerable percentage of BC cases, and unfortunately, it is associated with poor prognoses and limited treatment options. In-depth information about TNBC, including its epidemiology, clinical expression, molecular features, and current diagnostic and treatment options, is provided in this research paper. In addition to examining ongoing research projects to better TNBC patient outcomes and treatment options, the report also suggests potential future routes for improved management tactics. The development of effective targeted treatments and individualized treatment plans for such a challenging disease necessitates an understanding of the distinctive characteristics of TNBC. This article contributes to continuing efforts to meet the unmet clinical requirements of patients affected by this aggressive BC subtype by offering insight into the complexity of TNBC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
